Endocrine immune-related adverse events can occur in response to immune checkpoint inhibitors and can be severe. However, in some cancer types, if treated appropriately with hormone-replacement therapies, certain endocrine immune-related adverse events have been reported to be associated with favourable prognoses, as outlined in this Review.
- Shintaro Iwama
- Tomoko Kobayashi
- Hiroshi Arima
